Opus Genetics officer proposes $34.4K share sale
An acquisition entry records 30,228 shares from an RSU grant vest on October 22, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Opus Genetics, Inc. officer George N Magrath reported a proposed sale of 9,591 common shares, with an aggregate market value of $34,383.74, through Raymond James & Associates, Inc., on or about October 23, 2026. The notice states the trade is not discretionary and the sale is required to cover tax obligations. It also lists 30,228 shares acquired from the issuer through an RSU grant vest on October 22, 2026.
Key Figures
Key Terms
RSU financial
Rule 144 regulatory
attorney-in-fact regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.